25d48b78-8622-42af-b33f-4034a42f30cb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- MITOTIC_SPINDLE+0.400
- PI3K_AKT_MTOR_SIGNALING+0.400
- TGF_BETA_SIGNALING+0.400
- UV_RESPONSE_DN+0.400
- ANDROGEN_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- ALLOGRAFT_REJECTION+0.200
- APOPTOSIS+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- ANGIOGENESIS-0.300
- KRAS_SIGNALING_DN-0.300
- COAGULATION-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- MYC_TARGETS_V1-0.200
- MYOGENESIS-0.200
- P53_PATHWAY-0.200
- APICAL_SURFACE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934738 | — | — | 0.706 |
| 2 | MNG746 | — | — | 0.704 |
| 3 | b35a4a43-866d-4781-a4a8-9e2e728202ba | — | — | 0.670 |
| 4 | f0e20c4e-ac0b-45e1-a53b-2de9a19843b1 | — | — | 0.667 |
| 5 | SJEPD030584_D1.RNA-Seq | EPN | Supratentorial EPN | 0.663 |
| 6 | b2ea247e-4d51-4d77-a1ef-281bf4dfe249 | — | — | 0.645 |
| 7 | TCGA-44-2656-01A-02R-A278-07 | — | cohortMD2 | 0.643 |
| 8 | SJEPD030766_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.639 |
| 9 | X51ef25f8.0e4b.4c31.bd54.aee0c5fc11d9 | — | cohortA1 | 0.638 |
| 10 | TCGA-D8-A1JG-01B-11R-A13Q-07 | — | C | 0.632 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |